Aquestive Therapeutics vs Rockwell Medical
AQST and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and RMTI compare
Aquestive Therapeutics is the larger company, worth 17 times as much as Rockwell Medical ($464M against $26.6M).
Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus −21.1% for Rockwell Medical).
Rockwell Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −145% at Aquestive Therapeutics.
Rockwell Medical scores higher on the StockData Score (11 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $26.6M |
| Share price | $3.70 | $6.61 |
| Change, 1 year | −31.4% | −28.1% |
| Change, 5 years | −41.9% | −86.3% |
| Beta (5Y) | 1.20 | 0.01 |
| Employees | 147 | 157 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.6× | 0.4× (better) |
| P/B | – | 0.8× |
| P/FCF | – | 17.3× |
| FCF yield | −9.9% | 5.8% (better) |
| Fair value | – | $32.27 |
| Margin of safety | – | 79.5% |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | −21.1% |
| Revenue growth, 5Y average | −0.58% | 2.2% (better) |
| Profitability | ||
| Gross margin | 67.0% (better) | 17.7% |
| Operating margin | −97.5% | −6.5% (better) |
| Net margin | −145% | −7.3% (better) |
| FCF margin | −85.0% | 2.2% (better) |
| Return on equity | – | −15.5% |
| Return on invested capital | – | −17.9% |
| Financial health | ||
| Debt / equity | – | 0.26 |
| Interest coverage | −4.7× | −4.0× (better) |
| Current ratio | 7.19 (better) | 3.25 |
| Altman Z-score | −3.57 (better) | −7.81 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 0.05% |
| Held by insiders | 3.2% | 100% |
| Insider net buying, 12 months | −$2.3M | −$11.6K (better) |
| Short interest, % of float | 24.1% | – |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.